Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 35-47

  Shanmugam, Muthu K ^a   Lee, Jong Hyun ^b   Chai, Edna Zhi Pei ^a   Kanchi, Madhu Mathi ^c   Kar, Shreya ^a,c   Arfuso, Frank ^d   Dharmarajan, Arunasalam ^d   Kumar, Alan Prem ^a,c,d,e   Ramar, Perumal Samy ^f   Looi, Chung Yeng ^g   Mustafa, Mohammad Rais ^g   Tergaonkar, Vinay ^h   Bishayee, Anupam ⁱ   Ahn, Kwang Seok ^b   Sethi, Gautam ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Kyung Hee University   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF NORTH TEXAS   (United States)

^f NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^g UNIVERSITY OF MALAYA   (Malaysia)

^h INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

ⁱ Larkin Health Science Institute   (United States)

Author keywords

Cancer; Chemoprevention; Natural products; Therapy; Transcription factors

Indexed keywords

BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

CANCER PREVENTION; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; DRUG DEVELOPMENT; HUMAN; METASTASIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; STRUCTURE ANALYSIS; TRANSCRIPTION FACTOR MODULATION; TUMOR CELL LINE; ANIMAL; CARCINOGENESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PLANT EXTRACTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84962056748     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.03.005     Document Type: Review

References (207)

1. [1] Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58 (2008), 71–96.
2. [2] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics for Hispanics/Latinos, 2012. CA. Cancer J. Clin. 62 (2012), 283–298.
3. [3] Deorukhkar, A., Krishnan, S., Sethi, G., Aggarwal, B.B., Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin. Investig. Drugs 16 (2007), 1753–1773.
4. [4] Shanmugam, M.K., Kannaiyan, R., Sethi, G., Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr. Cancer 63 (2011), 161–173.
5. [5] Kneller, R., The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9 (2010), 867–882.
6. [6] Tao, L., Zhu, F., Qin, C., Zhang, C., Chen, S., Zhang, P., et al. Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites. Sci. Rep., 5, 2015, 9325.
7. [7] Newman, D.J., Natural products as leads to potential drugs: an old process or the new hope for drug discovery. J. Med. Chem. 51 (2008), 2589–2599.
8. [8] Dias, D.A., Urban, S., Roessner, U., A historical overview of natural products in drug discovery. Metabolites 2 (2012), 303–336.
9. [9] Aggarwal, B.B., Sethi, G., Baladandayuthapani, V., Krishnan, S., Shishodia, S., Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J. Cell. Biochem. 102 (2007), 580–592.
10. [10] Garodia, P., Ichikawa, H., Malani, N., Sethi, G., Aggarwal, B.B., From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J. Soc. Integr. Oncol. 5 (2007), 25–37.
11. [11] Chai, E.Z., Siveen, K.S., Shanmugam, M.K., Arfuso, F., Sethi, G., Analysis of the intricate relationship between chronic inflammation and cancer. Biochem. J. 468 (2015), 1–15.
12. [12] Sethi, G., Shanmugam, M.K., Ramachandran, L., Kumar, A.P., Tergaonkar, V., Multifaceted link between cancer and inflammation. Biosci. Rep. 32 (2012), 1–15.
13. [13] Aggarwal, B.B., Vijayalekshmi, R.V., Sung, B., Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res: Off J Am Assoc. Cancer Res. 15 (2009), 425–430.
14. [14] Ahn, K.S., Aggarwal, B.B., Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056 (2005), 218–233.
15. [15] Sen, R., Baltimore, D., Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappaB by a posttranslational mechanism. Cell 47 (1986), 921–928.
16. [16] Karin, M., Greten, F.R., NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005), 749–759.
17. [17] Mukherjee, N., Houston, T.J., Cardenas, E., Ghosh, R., To be an ally or an adversary in bladder cancer: the NF-kappaB story has not unfolded. Carcinogenesis 36 (2015), 299–306.
18. [18] Shanmugam, M.K., Kumar, A.P., Tan, B.K.H., Sethi, G., Role of NF-KB in tumorigenesis. Forum Immunopathol. Dis. Therap. 4 (2013), 187–203.
19. [19] Mythily, D.V., Krishna, S., Tergaonkar, V., Pleiotropic effects of human papillomavirus type 16 E6 oncogene expression in human epithelial cell lines. J. Gen. Virol. 80:Pt 7 (1999), 1707–1713.
20. [20] Ahn, K.S., Sethi, G., Aggarwal, B.B., Nuclear factor-kappa B: from clone to clinic. Curr. Mol. Med. 7 (2007), 619–637.
21. [21] Dey, A., Wong, E., Kua, N., Teo, H.L., Tergaonkar, V., Lane, D., Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle 7 (2008), 3759–3767.
22. [22] Castro, C.N., Barcala Tabarrozzi, A.E., Winnewisser, J., Gimeno, M.L., Antunica Noguerol, M., Liberman, A.C., et al. Curcumin ameliorates autoimmune diabetes: evidence in accelerated murine models of type 1 diabetes. Clin. Exp. Immunol. 177 (2014), 149–160.
23. [23] Troselj, K.G., Kujundzic, R.N., Curcumin in combined cancer therapy. Curr. Pharm. Des. 20 (2014), 6682–6696.
24. [24] Shanmugam, M.K., Rane, G., Kanchi, M.M., Arfuso, F., Chinnathambi, A., Zayed, M.E., et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 20 (2015), 2728–2769.
25. [25] Baliga, M.S., Katiyar, S.K., Chemoprevention of photocarcinogenesis by selected dietary botanicals. Photochem. Photobiol. Sci. 5 (2006), 243–253.
26. [26] Jiang, A.J., Jiang, G., Li, L.T., Zheng, J.N., Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells. Mol. Biol. Rep. 42 (2015), 267–275.
27. [27] Bush, J.A., Cheung, K.J. Jr., Li, G., Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res. 271 (2001), 305–314.
28. [28] Siwak, D.R., Shishodia, S., Aggarwal, B.B., Kurzrock, R., Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104 (2005), 879–890.
29. [29] Divya, C.S., Pillai, M.R., Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. 45 (2006), 320–332.
30. [30] Liu, D., Chen, Z., The effect of curcumin on breast cancer cells. J. Breast Cancer 16 (2013), 133–137.
31. [31] Chiu, T.L., Su, C.C., Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int. J. Mol. Med. 23 (2009), 469–475.
32. [32] Sinha, D., Biswas, J., Sung, B., Aggarwal, B.B., Bishayee, A., Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr. Drug Targets 13 (2012), 1799–1819.
33. [33] Aggarwal, B.B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R.A., Bueso-Ramos, C.E., et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 11 (2005), 7490–7498.
34. [34] Deeb, D., Jiang, H., Gao, X., Hafner, M.S., Wong, H., Divine, G., et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 3 (2004), 803–812.
35. [35] Hong, J.H., Ahn, K.S., Bae, E., Jeon, S.S., Choi, H.Y., The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 9 (2006), 147–152.
36. [36] Ferreira, L.C., Arbab, A.S., Jardim-Perassi, B.V., Borin, T.F., Varma, N.R., Iskander, A., et al. Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer. Anticancer Agents Med. Chem., 2015.
37. [37] Lee, J.H., Koo, T.H., Yoon, H., Jung, H.S., Jin, H.Z., Lee, K., et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem. Pharmacol. 72 (2006), 1311–1321.
38. [38] Sethi, G., Ahn, K.S., Pandey, M.K., Aggarwal, B.B., Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109 (2007), 2727–2735.
39. [39] Kannaiyan, R., Shanmugam, M.K., Sethi, G., Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303 (2011), 9–20.
40. [40] He, D., Xu, Q., Yan, M., Zhang, P., Zhou, X., Zhang, Z., et al. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer, 9, 2009, 343.
41. [41] Huang, Q., Shen, H.M., Ong, C.N., Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem. Pharmacol. 68 (2004), 361–371.
42. [42] Shrimali, D., Shanmugam, M.K., Kumar, A.P., Zhang, J., Tan, B.K., Ahn, K.S., et al. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341 (2013), 139–149.
43. [43] Shanmugam, M.K., Rajendran, P., Li, F., Nema, T., Vali, S., Abbasi, T., et al. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J. Mol. Med. (Berl.) 89 (2011), 713–727.
44. [44] Shanmugam, M.K., Dai, X., Kumar, A.P., Tan, B.K., Sethi, G., Bishayee, A., Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. Biochem. Pharmacol. 85 (2013), 1579–1587.
45. [45] Shanmugam, M.K., Nguyen, A.H., Kumar, A.P., Tan, B.K., Sethi, G., Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. Cancer Lett. 320 (2012), 158–170.
46. [46] Gai, L., Cai, N., Wang, L., Xu, X., Kong, X., Ursolic acid induces apoptosis via Akt/NF-kappaB signaling suppression in T24 human bladder cancer cells. Mol. Med. Rep. 7 (2013), 1673–1677.
47. [47] Wang, J., Liu, L., Qiu, H., Zhang, X., Guo, W., Chen, W., et al. Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One, 8, 2013, e63872.
48. [48] Shanmugam, M.K., Ong, T.H., Kumar, A.P., Lun, C.K., Ho, P.C., Wong, P.T., et al. Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways. PLoS One, 7, 2012, e32476.
49. [49] Liu, J., Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49 (1995), 57–68.
50. [50] Shanmugam, M.K., Dai, X., Kumar, A.P., Tan, B.K., Sethi, G., Bishayee, A., Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence. Cancer Lett. 346 (2014), 206–216.
51. [51] Parikh, N.R., Mandal, A., Bhatia, D., Siveen, K.S., Sethi, G., Bishayee, A., Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem. Rev. 13 (2014), 793–810.
52. [52] Hwang, Y.J., Song, J., Kim, H.R., Hwang, K.A., Oleanolic acid regulates NF-kappaB signaling by suppressing MafK expression in RAW 264.7 cells. BMB Rep. 47 (2014), 524–529.
53. [53] Jasinski, M., Jasinska, L., Ogrodowczyk, M., Resveratrol in prostate diseases—a short review. Cent. Eur. J. Urol. 66 (2013), 144–149.
54. [54] Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2 (2009), 409–418.
55. [55] Carter, L.G., D'Orazio, J.A., Pearson, K.J., Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21 (2014), R209–25.
56. [56] Kundu, J.K., Shin, Y.K., Kim, S.H., Surh, Y.J., Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27 (2006), 1465–1474.
57. [57] Ren, Z., Wang, L., Cui, J., Huoc, Z., Xue, J., Cui, H., et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie 68 (2013), 689–694.
58. [58] Bishayee, A., Waghray, A., Barnes, K.F., Mbimba, T., Bhatia, D., Chatterjee, M., et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 27 (2010), 1080–1091.
59. [59] Li, Y., Kong, D., Wang, Z., Sarkar, F.H., Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 27 (2010), 1027–1041.
60. [60] Beltz, L.A., Bayer, D.K., Moss, A.L., Simet, I.M., Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med. Chem. 6 (2006), 389–406.
61. [61] Peng, G., Dixon, D.A., Muga, S.J., Smith, T.J., Wargovich, M.J., Green tea polyphenol (−)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol. Carcinog. 45 (2006), 309–319.
62. [62] Syed, D.N., Afaq, F., Kweon, M.H., Hadi, N., Bhatia, N., Spiegelman, V.S., et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 26 (2007), 673–682.
63. [63] Nihal, M., Ahsan, H., Siddiqui, I.A., Mukhtar, H., Ahmad, N., Wood, G.S., (−)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 8 (2009), 2057–2063.
64. [64] Zhang, G., Wang, Y., Zhang, Y., Wan, X., Li, J., Liu, K., et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr. Mol. Med. 12 (2012), 163–176.
65. [65] Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998), 4252–4263.
66. [66] Pan, H., Zhou, W., He, W., Liu, X., Ding, Q., Ling, L., et al. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-kappaB activity via the Notch-1 pathway. Int. J. Mol. Med. 30 (2012), 337–343.
67. [67] Dastjerdi, M.N., Kavoosi, F., Valiani, A., Esfandiari, E., Sanaei, M., Sobhanian, S., et al. Inhibitory effect of genistein on PLC/PRF5Hepatocellular carcinoma cell line. Int. J. Prev. Med., 6, 2015, 54.
68. [68] Zhang, B., Shi, Z.L., Liu, B., Yan, X.B., Feng, J., Tao, H.M., Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs. 21 (2010), 288–296.
69. [69] Li, F., Shanmugam, M.K., Chen, L., Chatterjee, S., Basha, J., Kumar, A.P., et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev. Res. 6 (2013), 843–854.
70. [70] O'Brien, P., Carrasco-Pozo, C., Speisky, H., Boldine and its antioxidant or health-promoting properties. Chem. Biol. Interact. 159 (2006), 1–17.
71. [71] Gerhardt, D., Bertola, G., Dietrich, F., Figueiro, F., Zanotto-Filho, A., Moreira Fonseca, J.C., et al. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3beta. Urol. Oncol. 32 (2014), 36 3e1–9.
72. [72] Gerhardt, D., Horn, A.P., Gaelzer, M.M., Frozza, R.L., Delgado-Canedo, A., Pelegrini, A.L., et al. Boldine: a potential new antiproliferative drug against glioma cell lines. Invest. New Drugs 27 (2009), 517–525.
73. [73] Paydar, M., Kamalidehghan, B., Wong, Y.L., Wong, W.F., Looi, C.Y., Mustafa, M.R., Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models. Drug Des. Dev. Ther. 8 (2014), 719–733.
74. [74] Noureini, S.K., Wink, M., Dose-dependent cytotoxic effects of boldine in HepG-2 cells-telomerase inhibition and apoptosis induction. Molecules 20 (2015), 3730–3743.
75. [75] Manosroi, A., Saraphanchotiwitthaya, A., Manosroi, J., In vivo immunomodulating activity of wood extracts from Clausena excavata Burm f. J. Ethnopharmacol. 102 (2005), 5–9.
76. [76] Arbab, I.A., Abdul, A.B., Sukari, M.A., Abdullah, R., Syam, S., Kamalidehghan, B., et al. Dentatin isolated from Clausena excavata induces apoptosis in MCF-7 cells through the intrinsic pathway with involvement of NF-kappaB signalling and G0/G1 cell cycle arrest: a bioassay-guided approach. J. Ethnopharmacol. 145 (2013), 343–354.
77. [77] Arbab, I.A., Looi, C.Y., Abdul, A.B., Cheah, F.K., Wong, W.F., Sukari, M.A., et al. Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, survivin downregulation, caspase-9, −3/7 activation, and NF-kappaB inhibition. Evid. Based Complement Altern. Med., 2012, 2012, 856029.
78. [78] Andas, A.R., Abdul, A.B., Rahman, H.S., Sukari, M.A., Abdelwahab, S.I., Samad, N.A., et al. Dentatin from Clausena excavata induces apoptosis in HepG2Cells via mitochondrial mediated signaling. Asian Pac. J. Cancer Prev. 16 (2015), 4311–4316.
79. [79] Shuai, K., Stark, G.R., Kerr, I.M., Darnell, J.E. Jr., A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261 (1993), 1744–1746.
80. [80] Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
81. [81] Subramaniam, A., Shanmugam, M.K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim. Biophys. Acta 1835 (2013), 46–60.
82. [82] Thakur, R., Trivedi, R., Rastogi, N., Singh, M., Mishra, D.P., Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci. Rep., 5, 2015, 10194.
83. [83] Kamran, M.Z., Patil, P., Gude, R.P., Role of STAT3 in cancer metastasis and translational advances. BioMed Res. Int., 2013, 2013, 421821.
84. [84] Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14 (2014), 736–746.
85. [85] Reuter, S., Gupta, S.C., Park, B., Goel, A., Aggarwal, B.B., Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 6 (2011), 93–108.
86. [86] Glienke, W., Maute, L., Wicht, J., Bergmann, L., Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 28 (2010), 166–171.
87. [87] Alexandrow, M.G., Song, L.J., Altiok, S., Gray, J., Haura, E.B., Kumar, N.B., Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur. J. Cancer Prev. 21 (2012), 407–412.
88. [88] Rahmani, A.H., Al Zohairy, M.A., Aly, S.M., Khan, M.A., Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways. BioMed Res. Int., 2014, 2014, 761608.
89. [89] Lin, L., Deangelis, S., Foust, E., Fuchs, J., Li, C., Li, P.K., et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol. Cancer, 9, 2010, 217.
90. [90] Rajendran, P., Li, F., Shanmugam, M.K., Kannaiyan, R., Goh, J.N., Wong, K.F., et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res. 5 (2012), 631–643.
91. [91] Kannaiyan, R., Hay, H.S., Rajendran, P., Li, F., Shanmugam, M.K., Vali, S., et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol. 164 (2011), 1506–1521.
92. [92] Subramaniam, A., Loo, S.Y., Rajendran, P., Manu, K.A., Perumal, E., Li, F., et al. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis 18 (2013), 1175–1187.
93. [93] Sethi, G., Chatterjee, S., Rajendran, P., Li, F., Shanmugam, M.K., Wong, K.F., et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol. Cancer, 13, 2014, 66.
94. [94] Wang, W., Zhao, C., Jou, D., Lu, J., Zhang, C., Lin, L., et al. Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3. Anticancer Res. 33 (2013), 4279–4284.
95. [95] Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., Takada, Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004), 2783–2840.
96. [96] Aggarwal, B.B., Ichikawa, H., Garodia, P., Weerasinghe, P., Sethi, G., Bhatt, I.D., et al. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin. Ther. Targets 10 (2006), 87–118.
97. [97] Aggarwal, B.B., Sethi, G., Ahn, K.S., Sandur, S.K., Pandey, M.K., Kunnumakkara, A.B., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091 (2006), 151–169.
98. [98] Harikumar, K.B., Aggarwal, B.B., Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7 (2008), 1020–1035.
99. [99] Trung, L.Q., Espinoza, J.L., An, D.T., Viet, N.H., Shimoda, K., Nakao, S., Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Mol. Nutr. Food Res., 2015.
100. [100] Chelsky, Z.L., Yue, P., Kondratyuk, T.P., Paladino, D., Pezzuto, J.M., Cushman, M., et al. A resveratrol analogue promotes ERKMAPK-dependent stat3 serine and tyrosine phosphorylation alterations and antitumor effects In vitro against human tumor cells. Mol. Pharmacol. 88 (2015), 524–533.
101. [101] Chung, S.S., Vadgama, J.V., Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling. Anticancer Res. 35 (2015), 39–46.
102. [102] Tang, S.N., Fu, J., Shankar, S., Srivastava, R.K., EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One, 7, 2012, e31067.
103. [103] Wang, Y., Ren, X., Deng, C., Yang, L., Yan, E., Guo, T., et al. Mechanism of the inhibition of the STAT3 signaling pathway by EGCG. Oncol. Rep. 30 (2013), 2691–2696.
104. [104] Kaymaz, B.T., Cetintas, V.B., Aktan, C., Kosova, B., MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin. Tumour Biol. 35 (2014), 8733–8742.
105. [105] Kensler, T.W., Wakabayashi, N., Biswal, S., Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 89–116.
106. [106] Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236 (1997), 313–322.
107. [107] Kong, A.N., Owuor, E., Yu, R., Hebbar, V., Chen, C., Hu, R., et al. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev. 33 (2001), 255–271.
108. [108] Li, H., Wang, F., Zhang, L., Cao, Y., Liu, W., Hao, J., et al. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell. Signal. 23 (2011), 1625–1632.
109. [109] Bryan, H.K., Olayanju, A., Goldring, C.E., Park, B.K., The Nrf2 cell defence pathway: Keap1-dependent and −independent mechanisms of regulation. Biochem. Pharmacol. 85 (2013), 705–717.
110. [110] Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 371 (2003), 887–895.
111. [111] Rushworth, S.A., Ogborne, R.M., Charalambos, C.A., O'Connell, M.A., Role of protein kinase C delta in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem. Biophys. Res. Commun. 341 (2006), 1007–1016.
112. [112] McNally, S.J., Harrison, E.M., Ross, J.A., Garden, O.J., Wigmore, S.J., Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int. J. Mol. Med. 19 (2007), 165–172.
113. [113] Chen, B., Zhang, Y., Wang, Y., Rao, J., Jiang, X., Xu, Z., Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. J. Steroid Biochem. Mol. Biol. 143 (2014), 11–18.
114. [114] Khor, T.O., Huang, Y., Wu, T.Y., Shu, L., Lee, J., Kong, A.N., Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 82 (2011), 1073–1078.
115. [115] Das, L., Vinayak, M., Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer. PLoS One, 10, 2015, e0124000.
116. [116] Shen, G., Xu, C., Hu, R., Jain, M.R., Gopalkrishnan, A., Nair, S., et al. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther. 5 (2006), 39–51.
117. [117] Khan, N., Afaq, F., Saleem, M., Ahmad, N., Mukhtar, H., Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res. 66 (2006), 2500–2505.
118. [118] Kweon, M.H., Adhami, V.M., Lee, J.S., Mukhtar, H., Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281 (2006), 33761–33772.
119. [119] Zhang, Z.M., Yang, X.Y., Yuan, J.H., Sun, Z.Y., Li, Y.Q., Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in colon cancer cells and BALB/c mice. Chin. Med. J. (Engl.) 122 (2009), 1660–1665.
120. [120] Kilic, U., Sahin, K., Tuzcu, M., Basak, N., Orhan, C., Elibol-Can, B., et al. Enhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate. Front Nutr., 1, 2014, 28.
121. [121] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997), 218–220.
122. [122] Chiou, Y.S., Tsai, M.L., Nagabhushanam, K., Wang, Y.J., Wu, C.H., Ho, C.T., et al. Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J. Agric. Food Chem. 59 (2011), 2725–2733.
123. [123] Bishayee, A., Barnes, K.F., Bhatia, D., Darvesh, A.S., Carroll, R.T., Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev. Res. 3 (2010), 753–763.
124. [124] Li, C., Xu, X., Wang, X.J., Pan, Y., Imine resveratrol analogues: molecular design, Nrf2 activation and SAR analysis. PLoS One, 9, 2014, e101455.
125. [125] Dinkova-Kostova, A.T., The role of sulfhydryl reactivity of small molecules for the activation of the KEAP1/NRF2 pathway and the heat shock response. Scientifica (Cairo), 2012, 2012, 606104.
126. [126] Zhang, Y., Ahn, Y.H., Benjamin, I.J., Honda, T., Hicks, R.J., Calabrese, V., et al. HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. Chem. Biol. 18 (2011), 1355–1361.
127. [127] Rotondo, S., Krauze-Brzosko, K., Manarini, S., Martelli, N., Pecce, R., Evangelista, V., et al. Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake. Br. J. Nutr. 99 (2008), 240–247.
128. [128] Wei, H., Wei, L., Frenkel, K., Bowen, R., Barnes, S., Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr. Cancer 20 (1993), 1–12.
129. [129] Liu, W., Tan, X., Shu, L., Sun, H., Song, J., Jin, P., et al. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer. Molecules 17 (2012), 9104–9115.
130. [130] Fu, Z., Malureanu, L., Huang, J., Wang, W., Li, H., van Deursen, J.M., et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat. Cell Biol. 10 (2008), 1076–1082.
131. [131] Wang, Z., Ahmad, A., Li, Y., Banerjee, S., Kong, D., Sarkar, F.H., Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 36 (2010), 151–156.
132. [132] So, P.L., Tang, J.Y., Epstein, E.H., Novel investigational drugs for basal cell carcinoma. Expert Opin. Investig. Drugs 19 (2010), 1099–1112.
133. [133] Ye, H., Holterman, A.X., Yoo, K.W., Franks, R.R., Costa, R.H., Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S phase. Mol. Cell. Biol. 19 (1999), 8570–8580.
134. [134] Kalin, T.V., Wang, I.C., Ackerson, T.J., Major, M.L., Detrisac, C.J., Kalinichenko, V.V., et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66 (2006), 1712–1720.
135. [135] Kim, I.M., Ackerson, T., Ramakrishna, S., Tretiakova, M., Wang, I.C., Kalin, T.V., et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 66 (2006), 2153–2161.
136. [136] Liu, M., Dai, B., Kang, S.H., Ban, K., Huang, F.J., Lang, F.F., et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 66 (2006), 3593–3602.
137. [137] Chan, D.W., Yu, S.Y., Chiu, P.M., Yao, K.M., Liu, V.W., Cheung, A.N., et al. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J. Pathol. 215 (2008), 245–252.
138. [138] Ahmed, M., Uddin, S., Hussain, A.R., Alyan, A., Jehan, Z., Al-Dayel, F., et al. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97 (2012), E1–E13.
139. [139] Wang, Z., Banerjee, S., Kong, D., Li, Y., Sarkar, F.H., Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 67 (2007), 8293–8300.
140. [140] Bektas, N., Haaf, A., Veeck, J., Wild, P.J., Luscher-Firzlaff, J., Hartmann, A., et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer, 8, 2008, 42.
141. [141] Li, Q., Zhang, N., Jia, Z., Le, X., Dai, B., Wei, D., et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 69 (2009), 3501–3509.
142. [142] Wang, I.C., Chen, Y.J., Hughes, D., Petrovic, V., Major, M.L., Park, H.J., et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 25 (2005), 10875–10894.
143. [143] Wang, X., Krupczak-Hollis, K., Tan, Y., Dennewitz, M.B., Adami, G.R., Costa, R.H., Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27Kip1 protein levels and increased Cdc25B expression. J. Biol. Chem. 277 (2002), 44310–44316.
144. [144] Zhang, J.R., Lu, F., Lu, T., Dong, W.H., Li, P., Liu, N., et al. Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells. J. Mol. Med. (Berl.) 92 (2014), 1319–1330.
145. [145] Bao, B., Wang, Z., Ali, S., Kong, D., Banerjee, S., Ahmad, A., et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell. Biochem. 112 (2011), 2296–2306.
146. [146] Wang, Z., Ahmad, A., Banerjee, S., Azmi, A., Kong, D., Li, Y., et al. FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm. Res. 27 (2010), 1159–1168.
147. [147] Tian, T., Li, J., Li, B., Wang, Y., Li, M., Ma, D., et al. Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells. Tumour Biol. 35 (2014), 4137–4145.
148. [148] Ning, Y., Li, Q., Xiang, H., Liu, F., Cao, J., Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells. Oncol. Rep. 27 (2012), 1857–1864.
149. [149] Rahman, K.W., Li, Y., Wang, Z., Sarkar, S.H., Sarkar, F.H., Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 66 (2006), 4952–4960.
150. [150] Ahmad, A., Ali, S., Wang, Z., Ali, A.S., Sethi, S., Sakr, W.A., et al. 3,3′-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1. Int. J. Cancer 129 (2011), 1781–1791.
151. [151] Ahmad, A., Ali, S., Ahmed, A., Ali, A.S., Raz, A., Sakr, W.A., et al. 3,3′-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PLoS One, 8, 2013, e54657.
152. [152] Greene, M.E., Blumberg, B., McBride, O.W., Yi, H.F., Kronquist, K., Kwan, K., et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4 (1995), 281–299.
153. [153] Elbrecht, A., Chen, Y., Cullinan, C.A., Hayes, N., Leibowitz, M., Moller, D.E., et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun. 224 (1996), 431–437.
154. [154] Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., et al. International Union of Pharmacology: LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 58 (2006), 726–741.
155. [155] Oberfield, J.L., Collins, J.L., Holmes, C.P., Goreham, D.M., Cooper, J.P., Cobb, J.E., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 6102–6106.
156. [156] Kliewer, S.A., Lehmann, J.M., Milburn, M.V., Willson, T.M., The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 54:345–367 (1999), 67–68 discussion.
157. [157] Michalik, L., Desvergne, B., Wahli, W., Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 4 (2004), 61–70.
158. [158] Liu, S.H., Shen, C.C., Yi, Y.C., Tsai, J.J., Wang, C.C., Chueh, J.T., et al. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br. J. Pharmacol. 160 (2010), 1963–1972.
159. [159] Lee, S., Kim, H., Kang, J.W., Kim, J.H., Lee, D.H., Kim, M.S., et al. The biflavonoid amentoflavone induces apoptosis via suppressing E7 expression, cell cycle arrest at sub-G(1) phase, and mitochondria-emanated intrinsic pathways in human cervical cancer cells. J. Med. Food 14 (2011), 808–816.
160. [160] Jacob, A., Wu, R., Zhou, M., Wang, P., Mechanism of the anti-inflammatory effect of Curcumin: PPAR-gamma Activation. PPAR Res., 2007, 2007, 89369.
161. [161] Semenza, G.L., Transcriptional regulation by hypoxia-inducible factor 1 molecular mechanisms of oxygen homeostasis. Trends Cardiovasc. Med. 6 (1996), 151–157.
162. [162] Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998), 485–490.
163. 2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp. Cell Res. 295 (2004), 340–349.
164. [164] Zhang, Q., Tang, X., Lu, Q., Zhang, Z., Rao, J., Le, A.D., Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 5 (2006), 1227–1238.
165. [165] Strofer, M., Jelkmann, W., Depping, R., Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 187 (2011), 393–400.
166. [166] Chen, F., Liu, Y., Wang, S., Guo, X., Shi, P., Wang, W., et al. Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1alpha and Nrf2. Pharmacogenomics 14 (2013), 1305–1317.
167. [167] Mitani, T., Harada, N., Tanimori, S., Nakano, Y., Inui, H., Yamaji, R., Resveratrol inhibits hypoxia-inducible factor-1alpha-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. J. Nutr. Sci. Vitaminol. (Tokyo) 60 (2014), 276–282.
168. [168] Bishayee, A., Petit, D.M., Samtani, K., Angioprevention is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. J. Carcinog. Mutagen., 1, 2010, 102.
169. [169] Yun, J.H., Park, Y.G., Lee, K.M., Kim, J., Nho, C.W., Curcumin induces apoptotic cell death via Oct4 inhibition and GSK-3beta activation in NCCIT cells. Mol. Nutr. Food Res. 59 (2015), 1053–1062.
170. [170] Leow, P.C., Tian, Q., Ong, Z.Y., Yang, Z., Ee, P.L., Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest. New Drugs 28 (2010), 766–782.
171. [171] Yoo, J.H., Lee, H.J., Kang, K., Jho, E.H., Kim, C.Y., Baturen, D., et al. Lignans inhibit cell growth via regulation of Wnt/beta-catenin signaling. Food Chem. Toxicol. 48 (2010), 2247–2252.
172. [172] Pajak, B., Kania, E., Gajkowska, B., Orzechowski, A., Lipid rafts mediate epigallocatechin-3-gallate- and green tea extract-dependent viability of human colon adenocarcinoma COLO 205 cells; clusterin affects lipid rafts-associated signaling pathways. J. Physiol. Pharmacol. 62 (2011), 449–459.
173. [173] Kang, Y.J., Park, H.J., Chung, H.J., Min, H.Y., Park, E.J., Lee, M.A., et al. Wnt/beta-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol. Pharmacol. 82 (2012), 168–177.
174. [174] Liu, H.P., Gao, Z.H., Cui, S.X., Sun, D.F., Wang, Y., Zhao, C.R., et al. Inhibition of intestinal adenoma formation in APC(Min/ + ) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta. PLoS One, 7, 2012, e33243.
175. [175] He, L., Lu, N., Dai, Q., Zhao, Y., Zhao, L., Wang, H., et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/beta-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology 312 (2013), 36–47.
176. [176] Jurenka, J.S., Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern. Med. Rev. 13 (2008), 128–144.
177. [177] Turrini, E., Ferruzzi, L., Fimognari, C., Potential effects of pomegranate polyphenols in cancer prevention and therapy. Oxid. Med. Cell Longev., 2015, 2015, 938475.
178. [178] Bhatia, D., Thoppil, R.J., Mandal, A., Samtani, K.A., Darvesh, A.S., Bishayee, A., Pomegranate bioactive constituents suppress cell proliferation and induce apoptosis in an experimental model of hepatocellular carcinoma: role of wnt/beta—catenin signaling pathway. Evid. Based Complement Altern. Med., 2013, 2013, 371813.
179. [179] Bishayee, A., Mandal, A., Trianthema portulacastrum Linn exerts chemoprevention of 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats. Mut. Res. 768 (2014), 107–118.
180. [180] Eferl, R., Wagner, E.F., AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3 (2003), 859–868.
181. [181] Dong, Z., Ma, W., Huang, C., Yang, C.S., Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (−)-epigallocatechin gallate, and theaflavins. Cancer Res. 57 (1997), 4414–4419.
182. [182] Okabe, S., Ochiai, Y., Aida, M., Park, K., Kim, S.J., Nomura, T., et al. Mechanistic aspects of green tea as a cancer preventive: effect of components on human stomach cancer cell lines. Jpn. J. Cancer Res. Gann. 90 (1999), 733–739.
183. 2 production in transformed and non-transformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis 21 (2000), 2035–2039.
184. [184] Chung, J.Y., Park, J.O., Phyu, H., Dong, Z., Yang, C.S., Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (−)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J. 15 (2001), 2022–2024.
185. [185] Sartippour, M.R., Shao, Z.M., Heber, D., Beatty, P., Zhang, L., Liu, C., et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J. Nutr. 132 (2002), 2307–2311.
186. [186] Slivova, V., Zaloga, G., DeMichele, S.J., Mukerji, P., Huang, Y.S., Siddiqui, R., et al. Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells. Nutr. Cancer 52 (2005), 66–73.
187. [187] Valachovicova, T., Slivova, V., Bergman, H., Shuherk, J., Sliva, D., Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Int. J. Oncol. 25 (2004), 1389–1395.
188. [188] Lau, T.Y., Leung, L.K., Soya isoflavones suppress phorbol 12-myristate 13-acetate-induced COX-2 expression in MCF-7 cells. Br. J. Nutr. 96 (2006), 169–176.
189. [189] Huang, S.C., Ho, C.T., Lin-Shiau, S.Y., Lin, J.K., Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem. Pharmacol. 69 (2005), 221–232.
190. [190] Kim, D.H., Na, H.K., Oh, T.Y., Shin, C.Y., Surh, Y.J., Eupatilin inhibits proliferation of ras-transformed human breast epithelial (MCF-10A-ras) cells. J. Environ. Pathol. Toxicol. Oncol. 24 (2005), 251–259.
191. [191] Wang, S.Y., Feng, R., Lu, Y., Bowman, L., Ding, M., Inhibitory effect on activator protein-1, nuclear factor-kappaB, and cell transformation by extracts of strawberries (Fragaria x ananassa Duch.). J. Agric. Food Chem. 53 (2005), 4187–4193.
192. [192] Ding, M., Feng, R., Wang, S.Y., Bowman, L., Lu, Y., Qian, Y., et al. Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J. Biol. Chem. 281 (2006), 17359–17368.
193. [193] Suh, S.J., Jin, U.H., Choi, H.J., Chang, H.W., Son, J.K., Lee, S.H., et al. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem. Pharmacol. 72 (2006), 1680–1689.
194. [194] Munroe, M.E., Arbiser, J.L., Honokiol, Bishop G.A., A natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J. Immunol. 179 (2007), 753–763.
195. [195] Liu, W.K., Cheung, F.W., Liu, B.P., Li, C., Ye, W., Che, C.T., Involvement of p21 and FasL in induction of cell cycle arrest and apoptosis by neochamaejasmin A in human prostate LNCaP cancer cells. J. Nat. Prod. 71 (2008), 842–846.
196. [196] Kim, J.M., Noh, E.M., Kwon, K.B., Kim, J.S., You, Y.O., Hwang, J.K., et al. Curcumin suppresses the TPA-induced invasion through inhibition of PKCalpha-dependent MMP-expression in MCF-7 human breast cancer cells. Phytomedicine 19 (2012), 1085–1092.
197. [197] Youn, G.S., Kwon, D.J., Ju, S.M., Rhim, H., Bae, Y.S., Choi, S.Y., et al. Celastrol ameliorates HIV-1 Tat-induced inflammatory responses via NF-kappaB and AP-1 inhibition and heme oxygenase-1 induction in astrocytes. Toxicol. Appl. Pharmacol. 280 (2014), 42–52.
198. [198] Duhon, D., Bigelow, R.L., Coleman, D.T., Steffan, J.J., Yu, C., Langston, W., et al. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol. Carcinog. 49 (2010), 739–749.
199. [199] Larsen, C.A., Dashwood, R.H., (−)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch. Biochem. Biophys. 501 (2010), 52–57.
200. [200] Koh, Y.W., Choi, E.C., Kang, S.U., Hwang, H.S., Lee, M.H., Pyun, J., et al. Green tea (−)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J. Nutr. Biochem. 22 (2011), 1074–1083.
201. [201] Larsen, C.A., Bisson, W.H., Dashwood, R.H., Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies. J. Med. Chem. 52 (2009), 6543–6545.
202. [202] Liu, Y., Liu, J.H., Chai, K., Tashiro, S., Onodera, S., Ikejima, T., Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J. Pharmacy Pharmacol. 65 (2013), 1622–1642.
203. [203] Mehta, R., Katta, H., Alimirah, F., Patel, R., Murillo, G., Peng, X., et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One, 8, 2013, e65113.
204. [204] Tremblay, M.R., Lescarbeau, A., Grogan, M.J., Tan, E., Lin, G., Austad, B.C., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J. Med. Chem. 52 (2009), 4400–4418.
205. [205] Fan, Q., Gu, D., He, M., Liu, H., Sheng, T., Xie, G., et al. Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling. Chin.J. Cancer 30 (2011), 472–481.
206. [206] Wutka, A., Palagani, V., Barat, S., Chen, X., El Khatib, M., Gotze, J., et al. Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis. PLoS One, 9, 2014, e95605.
207. [207] Gao, Q., Yuan, Y., Gan, H.Z., Peng, Q., Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis. Oncol. Lett. 9 (2015), 2381–2387.